INFOS !
  • NEW ADDRESS: The management team of ERN-EYE is moving! Starting from March 19, you can find us at 1 Rue Eugène Boeckel, 67000 Strasbourg.

Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

In this page

Clinical Trial

NCT06627179 Recruiting, Active
LUNA

A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects with Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Phase 2
Interventional

Disease

Disease type

Usher Syndrome

Orphan drug recognition

Yes

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

11/12/2024

Closing date

31/12/2027

Inclusion criteria :

More

Exclusion criteria :

More

Funding

Industry

Members involved

Main investigators

Pr Camiel BOON

Representative

Netherlands

Anterior Segment Rare Eye Diseases (WG4), Genetic Diagnostics (TWG6), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

ERN EYE member investigating site

HCP : Principal investigators